Condition: Schizophrenia · Autism-Related Irritability · Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Local Institution - 0054 | Dothan, Alabama, United States | Not Yet Recruiting |
| Local Institution - 0163 | Phoenix, Arizona, United States | Not Yet Recruiting |
| Advanced Research Center Inc. | Anaheim, California, United States | Recruiting |
| Local Institution - 0159 | Anaheim, California, United States | Not Yet Recruiting |
| Inland Psychiatric Medical Group. | Chino, California, United States | Recruiting |
| Local Institution - 0024 | Culver City, California, United States | Not Yet Recruiting |
| Local Institution - 0162 | Glendale, California, United States | Not Yet Recruiting |
| Local Institution - 0153 | Los Angeles, California, United States | Not Yet Recruiting |
| Local Institution - 0158 | Orange, California, United States | Not Yet Recruiting |
| Local Institution - 0083 | Redlands, California, United States | Not Yet Recruiting |
| Local Institution - 0089 | San Francisco, California, United States | Not Yet Recruiting |
| Local Institution - 0157 | San Rafael, California, United States | Not Yet Recruiting |
+ 83 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.